Package Leaflet: Information for the Patient
Xadago 50 mg, film-coated tablets
Xadago 100 mg, film-coated tablets
Safinamide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Xadago is a medicine that contains the active substance safinamide. It works to increase the level of a substance called dopamine in the brain, which is involved in controlling movement and is present in reduced amounts in the brains of patients with Parkinson's disease. Xadago is used to treat Parkinson's disease in adults.
In patients in the mid-to-advanced stages of the disease, who experience sudden changes between "ON" periods, when they are able to move, and "OFF" periods, when they have difficulty moving, Xadago is added to a stable dose of a medicine called levodopa, either on its own or in combination with other anti-Parkinson's medicines.
Do not take Xadago
You must wait at least 7 days between stopping treatment with Xadago and starting treatment with MAOIs or pethidine.
Warnings and precautions
Consult your doctor before starting to take Xadago.
Children and adolescents
Xadago is not recommended for use in children and adolescents under 18 years of age due to the lack of data on safety and efficacy in this population.
Taking Xadago with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Consult your doctor before taking the following medicines with Xadago:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Pregnancy
Xadago should not be used during pregnancy or in women of childbearing potential who are not using adequate contraception.
Breast-feeding
Xadago is likely to pass into breast milk. Xadago should not be used during breast-feeding.
Driving and using machines
During treatment with safinamide, drowsiness and dizziness may occur; patients should be cautious when using hazardous machinery or driving until they are reasonably certain that Xadago does not affect them in any way.
Before driving or using machines, ask your doctor for advice.
Take this medicine exactly as your doctor has told you.
If you are not sure, ask your doctor again.
The recommended starting dose of Xadago is one 50 mg tablet, which can be increased to one 100 mg tablet, once daily, preferably in the morning, by mouth with water. Xadago can be taken with or without food.
If you have moderate liver impairment, you should not take more than 50 mg per day. Your doctor will confirm if this applies to you.
If you take more Xadago than you should
If you have taken too many Xadago tablets, you may develop high blood pressure, anxiety, confusion, inattention, drowsiness, dizziness, nausea, or vomiting, dilated pupils, or develop involuntary muscle contractions. Contact your doctor immediately and take the Xadago packaging with you.
If you forget to take Xadago
Do not take a double dose to make up for forgotten doses. Skip the missed dose and take the next dose when it is normally due.
If you stop taking Xadago
Do not stop taking Xadago without consulting your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Seek medical attention in case of hypertensive crisis (very high blood pressure, collapse), neuroleptic malignant syndrome (confusion, sweating, stiffness, high temperature, increased level of the enzyme creatine kinase in the blood), serotonin syndrome (confusion, high blood pressure, muscle stiffness, hallucinations), and hypotension.
The following side effects have been reported in clinical trials with placebo-controlled studies in patients with mid-to-advanced Parkinson's disease (patients taking safinamide as an add-on to levodopa alone or in combination with other anti-Parkinson's medicines):
Common(may affect up to 1 in 10 people): insomnia, difficulty performing voluntary movements, drowsiness, dizziness, headache, worsening of Parkinson's disease, cataract, low blood pressure when standing up, nausea, and falls.
Uncommon(may affect up to 1 in 100 people): urinary tract infection, skin cancer, low iron levels in the blood, low white blood cell count, alteration of red blood cells, decreased appetite, high levels of fat in the blood, increased appetite, high blood sugar levels, seeing things that are not there, feeling sad, abnormal dreams, fear and anxiety, confusion, mood changes, increased interest in sex, abnormal perceptions and thoughts, agitation, sleep disorders, numbness, instability, loss of sensation, prolonged abnormal muscle contraction, headache, difficulty speaking, fainting, abnormal memory, blurred vision, blind spot, double vision, sensitivity to light, disorders of the light-sensitive layer at the back of the eye, redness of the eyes, increased eye pressure, feeling that the room is spinning, palpitations, rapid heart rate, irregular heart rate, slow heart rate, high blood pressure, low blood pressure, enlarged and twisted veins, cough, difficulty breathing, runny nose, constipation, heartburn, vomiting, dry mouth, diarrhea, abdominal pain, stomach upset, gas, feeling full, drooling, mouth ulcers, sweating, itching, sensitivity to light, redness of the skin, back pain, joint pain, cramps, stiffness, muscle pain, neck pain, joint pain, cyst in the joint, uncontrollable need to urinate (nocturia), increased urination, pus in the urine, difficulty urinating, prostate problems, breast pain, decreased effect of the medicine, intolerance to the medicine, feeling cold, feeling unwell, fever, dryness of the skin, eyes, or mouth, abnormal blood tests, abnormal heart tracing, abnormal kidney function tests, abnormal urine tests, decreased blood pressure, increased blood pressure, abnormal eye tests, fracture in the foot.
Rare(may affect up to 1 in 1,000 people): pneumonia, skin infection, sore throat, nasal allergy, tooth infection, viral infection, non-cancerous skin growths/disorders, white blood cell abnormalities, severe weight loss, high potassium levels in the blood, uncontrolled impulses, stupor, disorientation, misperception of images, decreased interest in sex, thoughts that cannot be shaken off, feeling of being persecuted, premature ejaculation, uncontrollable need to sleep, fear of social situations, suicidal thoughts, clumsiness, ease of distraction, loss of sense of taste, weak or slow reflexes, pain in the legs that radiates, uncontrollable urge to move the legs, feeling of sleep, eye abnormalities, progressive loss of vision due to diabetes, increased tearing, night blindness, crossed eyes, heart attack, constriction or narrowing of blood vessels, very high blood pressure, chest tightness, difficulty speaking, difficulty or pain when swallowing, gastroduodenal ulcer, nausea, stomach bleeding, yellowing of the skin and mucous membranes (jaundice), hair loss, blistering, skin allergy, skin disorders, bruising, scaly skin, night sweats, skin pain, skin discoloration, psoriasis, flaky skin, inflammation of the spine joints due to an autoimmune disease, back pain, joint inflammation, musculoskeletal pain, muscle pain, neck pain, joint pain, cyst in the joint, uncontrollable need to urinate (nocturia), increased urination, pus in the urine, difficulty urinating, prostate problems, breast pain, decreased effect of the medicine, intolerance to the medicine, feeling cold, feeling unwell, fever, dryness of the skin, eyes, or mouth, abnormal blood tests, abnormal heart tracing, abnormal kidney function tests, abnormal urine tests, decreased blood pressure, increased blood pressure, abnormal eye tests, fracture in the foot.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after "EXP".
The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What Xadago contains
Appearance and packaging
Xadago 50 mg film-coated tablets are orange to copper-colored, round, biconvex with metallic luster, and 7 mm in diameter, marked with a "50" on one side of the tablet.
Xadago 100 mg film-coated tablets are orange to copper-colored, round, biconvex with metallic luster, and 9 mm in diameter, marked with a "100" on one side of the tablet.
Xadago is available in packs containing 14, 28, 30, 90, or 100 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder
Zambon S.p.A.
Via Lillo del Duca 10
20091 Bresso (MI)
Italy
Tel: +39 02665241
Fax: +39 02 66501492
e-mail: info.zambonspa@zambongroup.com
Manufacturer
Catalent Germany Schorndorf GmbH
Steinbeisstrasse 2
D- 73614 Schorndorf
Germany
Zambon S.p.A.
Via della Chimica, 9
36100 Vicenza
Italy
You can obtain further information on this medicine from the local representative of the marketing authorisation holder:
Belgium/Belgique/Belgien/ | France |
Luxembourg/Luxemburg | Zambon France S.A. |
Zambon N.V./S.A. | Tél: + 33 (0)1 58 04 41 41 |
Tél/Tel: + 32 2 777 02 00 | |
Bulgaria/Česká republika/Eesti/Ελλάδα/ | United Kingdom |
Hrvatska/Ireland/Ísland/Κύπρος/Latvija/ | Profile Pharma Limited |
Lietuva/Magyarország/Malta/Polska/ | Tel: + 44 (0) 800 0288 942 |
România/Slovenija/Slovenská republika | Italy |
Zambon S.p.A. | |
Тел./Tel/Τηλ/Sími: + 39 02665241 | Zambon Italia S.r.l. |
Tel: + 39 02665241 | |
Danmark/Norge/Suomi/Finland/Sverige | Nederland |
Zambon Sweden, Filial of Zambon Nederland B.V. | Zambon Nederland B.V. |
Tlf/Puh/Tel: + 47 815 300 30 | Tel: + 31 (0)33 450 4370 |
Deutschland/Österreich | Portugal |
Zambon GmbH | Zambon - Produtos Farmacêuticos, Lda. |
Tel: 00800 92626633 | Tel: + 351 217 600 952 / 217 600 954 |
España | |
Zambon, S.A.U. | |
Tel: + 34 93 544 64 00 | |
Date of last revision of this leaflet:. | |
Other sources of information |
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
The average price of XADAGO 100 mg FILM-COATED TABLETS in October, 2025 is around 121.69 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.